How Scalable Clinical Data Support Achieved a 42-Day Data Lock in a Phase III Oncology Trial

Large Phase III oncology trials generate complex clinical datasets across multiple sites. As the study progressed, several operational bottlenecks emerged:

• High volumes of data queries slowed clinical database reconciliation.
• Significant SDV backlog across multiple study sites.
• Internal CRO teams overwhelmed with verification and documentation tasks.
• Adverse event coding and SAE narrative preparation pending for regulatory documentation.
• The database lock, originally projected to take 14 weeks, risked slipping further as the backlog grew.

For a Phase IIIoncology program of this scale, even a small delay can have major financial consequences. A delayed NDA submission can cost sponsors over $1 million per month in lost market access opportunity.

The company needed a partner who could move fast and grow with the project without ever dropping the ball on quality or strict medical rules.

LezDo TechMed brought in a specialized team of data experts to get everything back on track. Our mission was simple: speed up the paperwork and double-check every single detail. We didn't cut corners, we just worked smarter. By following the "gold standard" of clinical rules (like GCP and 21 CFR Part 11), we ensured the company stayed fully compliant and ready for regulation.

We made sure every step followed the "gold standard" of medical rules (like GCP and 21CFR Part 11), keeping the company fully compliant with government regulations.

Making sure the data was flawless

Our team performed a "100% match" check. They compared every single physical patient record against the digital database to make sure they were identical. By catching and fixing these tiny mismatches early, we made the study’s data much more reliable and ready for the finish line.

Medical history abstraction

Clinical documentation specialists extracted relevant patient history data from medical records and structured it for database alignment, improving accessibility for investigators and study managers.

Query resolution

LezDo TechMed’s team worked directly with CRO data managers and site coordinators to review documentation, validate discrepancies, and resolve outstanding queries, clearing the backlog and improving data readiness.

Adverse event coding

We coded more than 1,200 adverse events using MedDRA standards, making sure every medical issue was labeled correctly and ready for official review.

SAE narrative preparation

The team also prepared Serious Adverse Event (SAE) narratives required for regulatory documentation, supporting safety reporting and submission readiness.

The engagement was executed over 11 weeks, from initial onboarding through database lock support.

The execution model focused on structured workflows and strict quality assurance:

• Dedicated SDV and data abstraction teams assigned by site cluster
• Two-level clinical review system for quality validation
• 10% random QC sampling across completed SDV batches
• Error tolerance maintained below 1% discrepancy rate
• Continuous coordination with CRO data managers to prioritize high-risk data queries

This structured operational framework allowed the team to rapidly clear the backlog while maintaining regulatory-grade data quality.

Before vs After: Clinical Trial Data Operations Performance

450 patient records reviewed

Comprehensive clinical documentation review ensured data accuracy across all participating sites.

1,200+ adverse events coded to MedDRA

Standardized safety coding improved clarity and consistency of adverse event reporting.

42-day acceleration in database lock

What was supposed to take 14 weeks was finished in under 8, getting the study to the finish line over a month ahead of schedule.

On-time NDA submission maintained

Most importantly, the sponsor preserved the regulatory submission timeline and avoided a potential delay in market access.

Business Impact

For late-stage clinical trials, operational delays can have significant downstream consequences.

By maintaining the planned submission timeline, the sponsor avoided a potential 6–8 week regulatory delay, which could have resulted in millions of dollars in lost revenue opportunity due to delayed market entry.

By restoring clinical data operations to full capacity within 11 weeks, LezDo TechMed enabled the sponsor to achieve database lock ahead of the original 14-week projection and proceed with NDA submission on schedule. For a Phase III oncology program approaching commercialization, that outcome represented not just a preserved timeline — but a preserved market opportunity.

Client Testimonial

"LezDo TechMed's team integrated into our trial operations within days. Their ability to handle the SDV backlog while simultaneously managing AE coding gave us the confidence to proceed with NDA submission on schedule."

— Clinical Operations Director (Client identity withheld under confidentiality agreement)

Reviewed By:

A Senior Clinical Data Manager with 6+ years of Phase II–III trial support experience

LezDo TechMed Clinical Operations Team.